Calidi Biotherapeutics, Inc. · AMEX:CLDI
Calidi Biotherapeutics — SPAC Merger (February 2022)
36 slides from Calidi Biotherapeutics's SPAC merger presentation, Feb 2, 2022
Slide 1: Calidi Biotherapeutics Investor Presentation February 2022
is a clinical - stage biopharmaceutical company u tilizing stem cell - based platforms to revolutionize oncolytic virotherapies February 2022
Slide 2: Disclaimer
Investor Presentation Disclaimer This presentation (the “Presentation”) is for informational purposes only with respect to the proposed business combination b etw een Edoc Acquisition Corp. (“ Edoc ”) and Calidi Biotherapeutics, Inc. (together with its subsidiaries and divisions, “ Calidi ” or the “
Slide 3: Forward-looking statements
Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the occ urr ence of any event, change or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the Busi
Slide 4: Transaction Summary
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending Transaction Summary Page 4 Transaction Details Overview Edoc Acquisition Corp. (NASDAQ: ADOC) is a publicly - listed special purpose acquisition company with $92M in cash $25M PIPE and $75M ELOC raised in support o
Slide 5: Transaction Overview: Sources and Uses
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending Page 5 (1) The amounts from the various sources of cash may change based on (i) the amount of Public Stockholder redemptions prior to Cl osi ng, (ii) investor interest in the Acquisition and (iii) the then current
Slide 6: Company Overview: Seeking to Eradicate Cancers
Two Differentiated Stem Cell Platforms Large Target Markets in Areas of High Unmet Need Cutting Edge Stem Cell Manufacturing Processes Three Validated Development Programs Company Overview: Seeking to Eradicate Cancers Harnessing Allogeneic Cell - Based Immunotherapy Platforms © 2022 Calidi Biothera
Slide 7: Experienced Team with Proven Track Record
Experienced Team with Proven Track Record ALLAN CAMAISA Chairman & CEO STEPHEN THESING CBO BORIS MINEV, M.D. President, Medical & Scientific Affairs, Acting CMO TONY KALAJIAN acting CFO THOMAS HERRMANN, PH.D. AVP, R&D WENDY PIZARRO, ESQ. CAO/CLO BARBARA HAERTL, PH.D. AVP, Manufacturing Operations AN
Slide 8: Board of Directors
Board of Directors Allan Camaisa Chairman & CEO . Led $ 20 M early - stage Series A round and oversaw collaboration agreement with National Institutes of Health . Led key account engagements, including Roche, Johnson & Johnson, the US Veterans Administration, and CMS . Ernst and Young Entrepreneur o
Slide 9: Edoc Acquisition Corp. Board/Advisor Synergies
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending Edoc Acquisition Corp. Board/Advisor Synergies Page 9 Dr. Gang Li, M.D., Ph.D., Member of Board of Directors Adjunct clinical faculty member at the Stanford University Pain Management Center Solid healthcare manage
Slide 10: Current Obstacles to Oncolytic Viral Therapy
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending Current Obstacles to Oncolytic Viral Therapy Page 10 Challenges using Oncolytic Viruses: The naked oncolytic viruses are quickly eliminated by the patient’s immune system This leads to limited therapeutic potential
Slide 11: Calidi's Solution: Stem Cell-Based Platforms
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending CALIDI’S SOLUTION: Stem Cell - Based Platforms to Potentiate Oncolytic Viral Therapies Page 11 Stem cells loaded with oncolytic viruses are manufactured in a single off - the - shelf vial 1. Stem cell loaded with O
Slide 12: Induction of Anti-Tumor Immune Response
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending Induction of Anti - Tumor Immune Response CALIDI’S ADVANCED THERAPEUTIC CANDIDATES ARE INTENDED TO ACT AS MONOTHERAPY OR IN COMBINATION WITH IMMUNO - ONCOLOGY AGENTS (CHECKPOINT INHIBITORS OR CAR - T, AMONG OTHERS)
Slide 13: Differentiated, Wholly-Owned Pipeline
Differentiated, Wholly - Owned Pipeline Targeting Multiple Cancer Indications & Non - Cancer Indications © 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending Program Description Target Indications Discovery Non - clinical studies Phase 1 Phase 2 Phase 3 Calidi Worldw
Slide 14: Calidi's Cell-Based Oncolytic Virus Platform Advantages
Design for both intratumoral and systemic administration Resistance to rapid elimination by humoral immune system Higher amplification potential, reducing amount of required viral particles Viral - encoded therapeutic proteins are expressed at time of administration, immediately altering the TME Com
Slide 15: Market Size (Seven Major Markets)
Market Size (Seven Major Markets 1 ) Note: Prostate (all cases), Melanoma (all cases), TN=triple negative, Bladder (all cases) 1 U.S, Japan, and EU5 Indication CAGR (%) Head and Neck Cancer 21.6% Melanoma 5.28% Breast Cancer (TN) 11.22% Glioblastoma 7.54% 2020 2021 2022 2023 2024 2025 2026 Head and
Slide 16: NeuroNova Platform
© 2022 Calidi Biotherapeutics Ρ | Proprietary & Confidential, Patents issued and pending NeuroNova Platform 16
Slide 17: Glioblastoma Market: Addressing an Urgent Unmet Medical Need
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending 2.14 4.2 0 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 Market Size ($ billions) Global GBM Market Size Glioblastoma Market: Addressing an Urgent Unmet Medical Need 5 - year survival rate of 5%, median overall survival from first
Slide 18: NeuroNova (NNV1) Platform Overview
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending NeuroNova (NNV1) Platform Overview Image Source: Lancet Oncology Journal (June 29 th , 2021) » Possess inherent ability to distribute throughout tumor mass as well as migrate to distant tumor sites regardless of tu
Slide 19: NNV1 Phase 1 Trial Design
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending Neural Stem Cell Delivery of an Oncolytic Adenovirus in Newly Diagnosed Patients with Malignant Glioma: A First - in - Human, Phase 1 Clinical Trial (Lancet Oncology, 2021 Aug;22(8):1103 - 1114) NNV1 (NSC.CRAd - S
Slide 20: NNV1 Clinical Trial Results
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending NNV1 Clinical Trial Results Image Source: Lancet Oncology Journal (June 29 th , 2021) Treatment with NNV1 (NSC - CRAd - S - pk7) was safe and tolerable Treatment achieved favorable therapeutic outcomes in patients
Slide 21: SuperNova Platform
© 2022 Calidi Biotherapeutics Ρ | Proprietary & Confidential, Patents issued and pending SuperNova Platform 21
Slide 22: Solid Tumors: Overview
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending $121.3 $424.6 $0 $50 $100 $150 $200 $250 $300 $350 $400 $450 Market Size ($ billions) Global Solid Tumor Market Size Solid Tumors: Overview 2020 2028 CAGR: 15.0% Source: Research and Markets; Cancer.org Page 22 1 i
Slide 23: SuperNova Platform Overview
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending SuperNova Platform Overview » AD - MSC have significant advantages over other MSCs because of their ease of extraction, maintained potency with age of the donor, significant anti - inflammatory & immune - suppressi
Slide 24: SNV0: Phase 1 Trial Design
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending First - in - human study of TK - positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells SNV0: Phase 1 Trial Design Agent: SNV0: Adipose - derived autologous cells loaded with CAL1 –
Slide 25: Patient Case: Patient #SI01-047
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending SI - 001 Patient Case: Patient #SI01 - 047 • Age/Sex: 68/M • Diagnosis: Thyroid Papillary Carcinoma • Stage IV • Treatment Date / Location: 7/19/17 BH • Treatment Details: IT in right lesion 37x10 6 SC in 0.75ml -
Slide 26: Patient Case: Patient #SI01-021
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending SI - 001 Patient Case: Patient #SI01 - 021. Day 52 post Day 194 post • Age/Sex: 70/M • Diagnosis: Metastatic Head & Neck SCC • Stage IV_B • Injected tumor was resistant to chemo - and radio - therapy • Treatment Da
Slide 27: SNV0: Autologous Stem Cell Platform Has Promise in Multiple Indications
SNV0: Autologous Stem Cell Platform has Promise to Work in Multiple Indications © 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending Discontinued monitoring of patients 1 year following their treatment Page 27
Slide 28: SuperNova Clinical Observations and Development Pathway
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending Combined application of stem cells and vaccina virus was observed to be safe in all patients Results of the plasma cytokine assays suggested inflammatory reaction starting approximately 1 week after treatment. No c
Slide 29: Manufacturing and IP
© 2022 Calidi Biotherapeutics Ρ | Proprietary & Confidential, Patents issued and pending Manufacturing and IP
Slide 30: GMP Manufacturing for NeuroNova and SuperNova
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending GMP Manufacturing for NeuroNova (NNV) and SuperNova (SNV) PROVEN PARTNERS AND PROCESSES: NNV: City of Hope – proven GMP track - record and ongoing production of CRAD - S - Pk7 SNV: Genscript ongoing production of C
Slide 31: Broad IP Protection Across All Clinical Programs
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending Broad IP Protection Across All Clinical Programs in Development Allogeneic Adipose Tissue - derived and Neural Stem Cell Platforms for Delivery of Oncolytic Viruses Tropic Cell - Based Virotherapy for the Treatment
Slide 32: Upcoming Milestones
Upcoming Milestones Page 32 Program Milestone Timing SNV1 Pre - IND Meeting √ Corporate Genscript Sales & Distribution Agreement √ NNV1 Northwestern University / City of Hope Agreements √ NNV1 GMP Manufacturing Completion 2H 2022 SNV1 cGMP Final Drug Product Manufacturing Completion 1H 2023 NNV2 Pha
Slide 33: Company Overview: Seeking to Eradicate Cancers
Two Differentiated Stem Cell Platforms Large Target Markets in Areas of High Unmet Need Cutting Edge Stem Cell Manufacturing Processes Three Validated Development Programs Company Overview: Seeking to Eradicate Cancers Harnessing Allogeneic Cell - Based Immunotherapy Platforms © 2022 Calidi Biothera
Slide 34: Appendix
© 2022 Calidi Biotherapeutics Ρ | Proprietary & Confidential, Patents issued and pending Appendix
Slide 35: NeuroNova Innovators and KOLs
NeuroNova Innovators and KOLs Page 35 Karen Aboody, MD » Professor, Department of Stem Cell Biology, City of Hope Cancer Center » Documented safety of administering therapeutic NSCs into the brain tumor resection cavity Successful proof of concept for stem cell - based tumor targeting » NeuroNova co
Slide 36: Edoc Acquisition Corp. Overview
© 2022 Calidi Biotherapeutics, Inc. І Company Proprietary; Patents issued and pending Edoc Acquisition Corp. Overview Page 36 Seasoned management team with rich experience and complementary skill set in healthcare investment, management and technology development Extensive network of Chinese America